Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Pharma Tries Out New Class On The Diabetes Block: SGLT-2

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Could controlling type 2 diabetes be as simple as dumping excess sugar out of the body via the urine? Some Big Pharmas are betting on it, and with good Phase II results rolling in, enthusiasm is growing for a new mechanism of action that targets glucose in the kidneys instead of tinkering with insulin.

You may also be interested in...



FDA Warning On SGLT-2 Drugs Raises Specter Of Labeling Change

FAERS reports identify cases of diabetic ketoacidosis, ordinarily rare in type 2 diabetes, which were not associated with high blood sugar levels.

MannKind’s Long, Winding Development Road Ends In Approval Of Afrezza Inhaled Insulin

Firm now faces the commercial gauntlet of establishing an inhaled insulin in the crowded diabetes market.

AstraZeneca’s Farxiga Label Includes, But Downplays, Bladder Cancer Risk

AstraZeneca’s SGLT-2 inhibitor Farxiga (dapagliflozin) finally clears FDA, and without a black box warning on bladder cancer risk – allowing the drug to compete with J&J’s first-to-market Invokana.

Related Content

Topics

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel